Early use of thiopurines or methotrexate reduces major abdominal and perianal surgery in Crohn's disease

Inflammatory Bowel Diseases

Volumn 20, Issue 8, 2014, Pages 1382-1390

  Kariyawasam, Viraj C ^a,b   Selinger, Christian P ^a,c   Katelaris, Peter H ^a,b   Jones, D Brian ^a,b   McDonald, Charles ^a   Barr, Gavin ^a   Chapman, Grace ^a   Colliwshaw, James ^a   Lunney, Paul C ^a,b   Middleton, Kate ^a,b   Wang, Rosy R ^a,b   Huang, Tony ^a,d   Andrews, Jane ^e   Leong, Rupert W ^a,e  

^a ANZAC Research Institute   (Australia)

^b University of Sydney   (Australia)

^c NATIONAL HEALTH SERVICE   (United Kingdom)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Azathioprine; Crohn's disease; Immunomodulator; Mercaptopurine; Methotrexate; Outcome; Surgery; Thiopurine; Treatment

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; METHOTREXATE; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL SURGERY; ABSCESS DRAINAGE; ADULT; AGED; ANUS DISEASE; ARTICLE; COLON DISEASE; COLON RESECTION; CROHN DISEASE; EARLY INTERVENTION; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; ILEORECTAL ANASTOMOSIS; ILEUM RESECTION; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MAJOR SURGERY; MALE; PREVALENCE; PRIORITY JOURNAL; PROPENSITY SCORE; REOPERATION; RISK REDUCTION; SMALL INTESTINE RESECTION; SMOKING; SURGICAL RISK; TOTAL COLON RESECTION; TREATMENT OUTCOME; ABDOMEN; ADOLESCENT; ANAL CANAL; CHILD; CLINICAL TRIAL; LONGITUDINAL STUDY; MIDDLE AGED; MULTICENTER STUDY; PRESCHOOL CHILD; PROGNOSIS; RETROSPECTIVE STUDY; SECONDARY PREVENTION; VERY ELDERLY; YOUNG ADULT;

6-MERCAPTOPURINE; ABDOMEN; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANAL CANAL; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; MALE; METHOTREXATE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; YOUNG ADULT;

EID: 84905509865     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000119     Document Type: Article

References (35)

1. Bouguen G, Peyrin Biroulet L. Surgery for adult Crohn's disease: what is the actual risk? Gut. 2011;60:1178-1181.
2. Ramadas AV, Gunesh S, Thomas GAO, et al. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut. 2010;59:1200-1206.
3. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431-440.
4. Munkholm P. Crohn's disease-occurrence, course and prognosis. An epidemiologic cohort-study. Danish Medical Bulletin. 1997;44:287-302.
5. Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish crohn colitis database. Am J Gastroenterol. 2006;101:1274-1282.
6. Lakatos PL, Golovics PA, David G, et al. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from western Hungary between 1977-2009. Am J Gastroenterol. 2012;107:579-588.
7. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, et al. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol. 2012;107:1693-1701.
8. Cannom RR, Kaiser AM, Ault GT, et al. Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates? Am Sergeon. 2009;75:976-980.
9. Jones DW, Finlayson SRG. Trends in surgery for Crohn's disease in the era of infliximab. Ann Surg. 2010;252:307-312.
10. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54:237-241.
11. Panés J, San Román AL, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology. 2013;145:766-774.e1.
12. Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine versus conventional management of Crohn's disease: a randomized controlled trial. Gastroenterology. 2013;145:758-765.e2.
13. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2010;6:CD000545.
14. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010;4:28-62.
15. Seinen ML, Ponsioen CY, de Boer NKH, et al. Sustained clinical benefit and tolerability of methotrexate monotherapy after thiopurine therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2013;11:667-672.
16. Selinger CP, Leong RW. Mortality from inflammatory bowel diseases. Inflamm Bowel Dis. 2012;18:1566-1572.
17. Wilson J, Hair C, Knight R, et al. High incidence of inflammatory bowel disease in Australia: a prospective population-based Australian incidence study. Inflamm Bowel Dis. 2010;16:1550-1556.
18. Selinger CP, Andrews JM, Titman A, et al. Long-term follow up reveals low incidence of colorectal cancer, but frequent need for resection, among Australian patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12:644-650.
19. Leong RW, Gearry RB, Sparrow MP. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol. Expert Opin Drug Saf. 2008;7:607-616.
20. Andrews JM, Norton I, Dent O, et al. Inflammatory bowel disease: a retrospective review of a specialist-based cohort. Med J Aust. 1995;163:133-136.
21. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;24:2-6.
22. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5-36.
23. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol. 1995;30:699-706.
24. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399-424.
25. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319:1492-1495.
26. Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology. 2008;135:1106-1113.
27. Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol. 2009;104:2089-2096.
28. Doherty G, Bennett G, Patil S, et al. Interventions for prevention of postoperative recurrence of Crohn's disease. Cochrane Database Syst Rev. 2009;4:CD006873.
29. Papay P, Reinisch W, Ho E, et al. The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery. Am J Gastroenterol. 2010;105:1158-1164.
30. Corte C, Saxena P, Tattersall S, et al. When to use biological agents in inflammatory bowel disease. J Gastroenterol Hepatol. 2012;27:1141-1149.
31. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of followup in the TREATTM registry. Am J Gastroenterol. 2012;107:1409-1422.
32. Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT registry. Am J Gastroenterol. 2014;109:212-223.
33. Rogler G, Sandborn WJ. Is there still a role for thiopurines in Crohn's disease? Gastroenterology. 2013;145:714-716.
34. Gearry RB, Richardson A, Frampton CMA, et al. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm Bowel Dis. 2006;12:936-943.
35. Frolkis AD, Dykeman J, Negrón ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145:996-1006.